Understanding the difference between non-GMP and GMP peptide synthesis is essential for researchers and pharmaceutical companies planning peptide-based projects. The choice between these two approaches has significant implications for quality, cost, timeline, and regulatory compliance.
Non-GMP peptide synthesis is suitable for early research applications including target validation, assay development, and SAR studies. Non-GMP peptides are produced under ISO-compliant conditions but without the full regulatory documentation required for clinical use. They offer flexibility, faster turnaround times, and lower costs compared to GMP production. Purity typically ranges from 70% to 98%, depending on the application requirements.
GMP (Good Manufacturing Practice) peptide synthesis follows strict regulatory guidelines established by agencies like the FDA and EMA. GMP production requires validated processes, comprehensive documentation, and rigorous quality control at every step. GMP peptides are essential for clinical trials, toxicology studies, and commercial products. They come with full regulatory documentation including batch records, validation reports, and stability data.
The transition from non-GMP to GMP synthesis requires careful planning to ensure process consistency. Ideally, the same synthesis route should be used for both, with additional controls and documentation added for GMP production. This approach minimizes the risk of changes in impurity profiles or product quality during technology transfer.
Key differences between non-GMP and GMP synthesis include documentation requirements (GMP requires comprehensive batch records and validation), facility requirements (GMP requires dedicated facilities with environmental monitoring), and quality control (GMP requires more extensive testing including stability studies).
At PeptideHub, we offer both non-GMP and GMP synthesis, with a clear transition path between the two. Our experienced team can guide you through the process, ensuring that your peptide meets the appropriate quality standards for each stage of development. This integrated approach minimizes risk and accelerates timelines, providing a seamless pathway from research to commercialization.